Casey N. Aitken

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

H. Tun, D. Brander, S. Schuster, 2019, Blood.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Deborah A. Bowen, A. Feldman, T. Habermann, 2017, Blood.